DLL3 and small cell lung carcinoma: Similarly, DLL3, an inhibitory ligand of the NOTCH pathway, may be a prospective target for the ASCL1 subtype, despite failure of the DLL3-targeted drug (rovalpituzumab tesirine, Rova-T) in SCLC, which may be closely associated with the undistinguished population [93, 94].